News
Aldosterone suppression testing is suggested where screening results indicate an intermediate probability for lateralizing PA and patients wish to pursue eligibility for surgical therapy.
Opioids administered or prescribed in 35.0 and 32.5% of U.S. visits in 2016, respectively, compared with 24.5 and 13.5% in 2022.
Discontinuation of GLP-1 receptor agonists suggested before conception rather than between start of pregnancy and end of first trimester.
HealthDay News — There was an overall decrease in influenza vaccine uptake among US adults from 2020 to 2024, according to a study published online July 16 in PLOS Global Public Health.
Topline data were announced from a phase 3 trial evaluating luspatercept-aamt plus Janus kinase 2 inhibitor (JAKi) therapy in adults with myelofibrosis-associated anemia receiving red blood cell (RBC) ...
The approval was supported by data from the randomized, double-blind, placebo-controlled, event-driven phase 3 FINEARTS-HF study.
The Food and Drug Administration (FDA) has approved a new prefilled syringe presentation of Shingrix (zoster vaccine recombinant, adjuvanted).
In 2022, the FDA had made the decision to ban the products because the applications lacked sufficient evidence to show they met a public health standard.
HealthDay News — US Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. has removed two senior officials who were appointed by President Donald Trump. Heather Flick Melanson, chief of ...
HealthDay News — Delays in diagnosis of hypertension are common and associated with delays in treatment initiation, according to a study published online July 14 in JAMA Network Open.
HealthDay News — The US Food and Drug Administration has announced a plan to revoke 52 food standards after concluding they ...
New indication for Kerendia; investigational therapy shows promise for hypertension; Novolog interchangeable biosimilar gets approval; trial results for hormone-free contraceptive; Shingrix now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results